Teligene US

Privately held: no public share price · United States

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 2
EGFRSmall molecule
Non-Small Cell Lung Cancer

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
December 2027 (2)
SutetinibPhase 2Non-small Cell Lung Cancer
Est. primary completion 2027-12 · NCT05168566 · CT.gov ↗
What to watch
SutetinibPhase 2Non-small Cell Lung Cancer
Est. primary completion 2027-12 · NCT06010329 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.